Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors
摘要:
Aiming to develop novel Type -I-1/2 inhibitors of ALK to overcome extensive resistance mutations, especially the L1196M mutation surrounding the ATP pocket, two series of 2-arylaminopyrimidine derivatives (11a-f and 22at) were designed based on scaffold hopping. The extensive structural elaboration discovered compound 22o which possessed excellent IC50 values of 0.06 and 0.23 mu M against ALK-positive Karpas299 and H2228 cell lines, respectively. Meanwhile, 22o displayed encouraging inhibitory potency in the ALK(WT) (2.5 nM) and ALK(L1196m )(6.5 nM) enzymatic assays. Furthermore, the AO/EB and Hoechst 33258 assays illustrated 22o could induce cell apoptosis in a dose-dependent manner. Eventually, the molecular docking of 22o with ALK clearly presented the vital interactions within the active site, which was in accordance with Type -I-1/2 inhibitor binding mode.
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
申请人:Schering AG
公开号:US20040204452A1
公开(公告)日:2004-10-14
The invention relates to the use of aromatics sulfonamides of the general formula I as peroxynitrite rearrangement catalysts, to the preparation thereof and to the use thereof as medicament for the treatment of various disorders.
1
[EN] AROMATIC SULFONAMIDES AS PEROXYNITRITE-REARRANGEMENT CATALYSTS<br/>[FR] SULFONAMIDES AROMATIQUES CONVENANT COMME CATALYSEURS D'INTERESTERIFICATION PEROXYNITRITIQUE
申请人:SCHERING AG
公开号:WO2004089882A2
公开(公告)日:2004-10-21
The invention relates to the use of aromatics sulfonamides of the general formula (I) as peroxynitrite rearrangement catalysts, to the preparation thereof and to the use thereof as medicament for the treatment of various disorders.